662 related articles for article (PubMed ID: 23000327)
1. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
[TBL] [Abstract][Full Text] [Related]
3. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
[TBL] [Abstract][Full Text] [Related]
4. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
[TBL] [Abstract][Full Text] [Related]
5. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
6. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
[TBL] [Abstract][Full Text] [Related]
7. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic and stratified value of adrenomedullin in community acquired pneumonia patients in emergency department].
Chen Y; Li C
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Feb; 26(2):115-9. PubMed ID: 24524403
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
[TBL] [Abstract][Full Text] [Related]
11. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
[TBL] [Abstract][Full Text] [Related]
13. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections.
Müller B; Süess E; Schuetz P; Müller C; Bingisser R; Bergmann A; Stolz D; Tamm M; Morgenthaler NG; Christ-Crain M
J Intern Med; 2006 Dec; 260(6):568-76. PubMed ID: 17116008
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.
Liu D; Xie L; Zhao H; Liu X; Cao J
BMC Infect Dis; 2016 May; 16():232. PubMed ID: 27230573
[TBL] [Abstract][Full Text] [Related]
16. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia.
Renaud B; Schuetz P; Claessens YE; Labarère J; Albrich W; Mueller B
Chest; 2012 Dec; 142(6):1447-1454. PubMed ID: 22661450
[TBL] [Abstract][Full Text] [Related]
17. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
[TBL] [Abstract][Full Text] [Related]
18. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia.
Christ-Crain M; Breidthardt T; Stolz D; Zobrist K; Bingisser R; Miedinger D; Leuppi J; Tamm M; Mueller B; Mueller C
J Intern Med; 2008 Aug; 264(2):166-76. PubMed ID: 18298480
[TBL] [Abstract][Full Text] [Related]
19. The value of procalcitonin level in community-acquired pneumonia in the ED.
Park JH; Wee JH; Choi SP; Oh SH
Am J Emerg Med; 2012 Sep; 30(7):1248-54. PubMed ID: 22030193
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification and prediction value of procalcitonin and clinical severity scores for community-acquired pneumonia in ED.
Zhou H; Guo S; Lan T; Ma S; Zhang F; Zhao Z
Am J Emerg Med; 2018 Dec; 36(12):2155-2160. PubMed ID: 29691103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
